IBRD4-BD1 (diTFA)

• Description:

  IBRD4-BD1 diTFA is selective BRD4 bromodomain inhibitor. iBRD4-BD1 diTFA has inhibition activity for BRD4 bromodomain with an IC50 value of 12 nM. iBRD4-BD1 diTFA can be used for the research of inflammation and oncology[1].

• UNSPSC:

  12352005

• Target:

  Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ibrd4-bd1-ditfa.html

• Purity:

  99.52

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  FC(F)(C1=CC=C(C2=C(C3=CC=NC(OC4=CC(C(C)C)=CC=C4C)=N3)N(C5CCNCC5)C=N2)C=C1)F.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O

• Molecular Formula:

  C33H32F9N5O5

• Molecular Weight:

  749.62

• References & Citations:

  [1]Anand Divakaran, et al. Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader. ACS Med Chem Lett. 2022 Sep 29;13 (10) :1621-1627.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2839318-20-4]